natgillin/translations-raw huggingface dataset:
C3-C4 cycloalkyl that is unsubstituted or substituted with one or more substituents selected from the group consisting of C1-C6 alkyl, C3-C7 cycloalkyl, and halogeno C1-C6 alkyl, 
-C7 cikloalkil koji može biti supstituiran sa C1-C6 alkilom, C3-C7 cikloalkilom, ili halogeno C1-C6 alkilom, -C12 premošteni cikloalkil, ili -C7 cikloalkenil.
The system of claim 1 wherein the plurality of neutral atom beam injectors are oriented with an injection path tangential to the FRC with a target trapping zone within separatrix of the FRC. 
Postupak prema zahtjevu 1, 4 do 5 i 7, naznačen time, da je mnoštvo injektora neutralnih atomskih zraka orijentirano s injektorskom putanjom tangencijalno na FRC-konfiguraciju sa zonom ciljnog zahvaćanja unutar separatriksa (451) od FRC.
a composition "comprising" X may consist exclusively of X or may include something additional e.g. 
sastav koji "sadrži" X može se sastojati isključivo od X ili može uključivati nešto dodatno, na pr.
Description of Preferred Embodiments of the Process 
Broj objave europskog patenta:
The veterinary or agricultural composition according to claim 26, wherein the insect growth regulator is selected from the group consisting of methoprene, pyriproxyfen, hydroprene, cyromazine, fluazuron, lufenuron, novalouron, pyrethroids, formamidines and 1-(2,6-difluorobenzoyl)-3-(2-fluoro-4-(trifluoromethyl))phenylurea. 
Veterinarski ili agrikulturni sastav prema zahtjevu 26, naznačen time, da je regulator rasta kukaca odabran iz skupine koja se sastoji od sljedećih: metopren, piriproksifen, hidropren, ciromazin, fluazuron, lufenuron, novalouron, piretroidi, formamidini i 1-(2,6-difluorobenzoil)-3-(2-fluoro-4-(trifluorometil)fenilurea.
The homozygous animals, C57 BL/KsJ-db/db mice developed by Jackson Laboratory are obese, hyperglycemic, hyperinsulinemic and insulin resistant [J Clin Invest (1990) 85:962-967], whereas heterozygotes are lean and normoglycemic. 
Homozigotne životinje, C57 BL/KsJ-db/db miševi uzgojeni u Jackon Labaratory su debeli, hiperglikemički, hiperinzulinemični i inzulin rezistentni [J Clin Invest (1990) 85:962-967], dok su heterozigoti mršavi i normoglikemični.
is 1-4C-alkyl, 1-4C-alkoxy or halogen, or a salt, a tautomer, or a stereoisomer thereof, or a salt of said tautomer or said stereoisomer. 
R9 je 1-4C-alkil, 1-4C-alkoksi ili halogen, ili sol, naročito farmaceutski prihvatljiva sol, tautomer, ili stereoizomer navedenog spoja, ili sol, naročito farmaceutski prihvatljiva sol navedenog tautomera ili navedenog stereoizomera.
Two further additions of boron trifluoride etherate (8.0 µL, 65 µmol) followed by stirring at room temperature for 2 h were carried out before evaporation of the solvent. 
Doda se još dva obroka bornog trifluorida eterata (8,0 ul, 65 umol) uz 2 sata miješanja na sobnoj temperaturi, nakon čega se otapalo otpari.
GDP Buffer: binding buffer plus GDP, ranging from 0.4 to 40 uM, make fresh before assay Procedure: 
10 mM MgC1, GDP pufer: vezivni pufer plus GDP, raspona od 0.4 do 40uM, svježe pripremljeno prije ispitivanja
For those reasons, the colon is the sector of the intestine most susceptible to infection; in fact, infections located in the colon (infectious colites, bacillary dysentery, diarrhoea, pseudomembranous colitis, diverticulitis, etc.) 
Iz tih je razloga kolon dio crijeva koje je najpodložnije infekcijama; naime infekcije smještene u kolonu (infektivni kolitis, bacilarna dizenterija, dijareja, pseudomembranski kolitis, divertikulitis, itd.)
In some embodiments, the transfecting or transducing of part (b) occurs in the same step as part (a) and the nucleic acid comprising a sequence encoding a nuclease or recombinase is a separate vector, plasmid, or nucleic acid molecule than the integration-defective vector of part (a). 
(b) transfekciju ili transdukciju kompatibilne stanice domaćina nukleinskom kiselinom koja sadrži sekvencu koja kodira nukleazu ili rekombinazu koja može posredovati u mjesto-specifičnoj integraciji u rekombinacijskoj sekvenci, izborno Cre ili Filp, gdje transfekcija ili transdukcija iz dijela (b) može se odvijati odvojeno ili u istom koraku kao dio (a),
A compound of formula (VI) wherein, R1 is C1-C6 alkyl (optionally substituted with 1, 2 or 3 fluorine atoms) or C3-C6 cycloalkyl wherein one C-C bond within the cycloalkyl moiety is optionally substituted by an O-C bond; 
R' je Cr-Cg alkil (izborno supstituiran s 1, 2 ili 3 atoma fluora) ili Ca-Cg cikloalkil, gdje jedna veza C-C u cikloalkilnom ostatku je izborno zamijenjena vezom O-C;
Furthermore, other objects of this invention concern the development of manufacturing methodologies that permit the preparation of ET-743 formulations with ET-743 concentrations that are higher than those achieved by conventional means. 
Osim toga, drugi ciljevi ovog izuma odnose se na razvoj metodologija proizvodnje koje omogućuju pripremu ET-743 oblika s koncentracijama ET-743 koje su više od onih postignutih uobičajenim sredstvima.
The starting compound of structural formula IV can be prepared by the procedures detailed in Schemes 1-3 and Example 1 below. 
Početni spoj strukturne formule TV može se pripraviti postupcima opisanim u Shemama 1-3 i Primjeru 1 dolje.
The production method of claim 17, which further comprises a step of producing a compound represented by the formula (2-B): wherein X200 is a halogen atom, or a salt thereof, from compound (1-B): or a salt thereof; 
Postupak dobivanja u skladu s patentnim zahtjevom 16, naznačen time što se dodatno sastoji u koraku dobivanja spoja prikazanog formulom (2-B):
The isolated IL-23p19 antibody of claim 1, further comprising at least one human framework region adjacent to a complementarity determining region. 
Izolirano IL-23p19 antitijelo iz zahtjeva 1, naznačeno time da dalje sadrži najmanje jednu ljudsku okvirnu regiju susjednu sa najmanje jednom komplementarnom određujućom regijom.
The corresponding benzoic acids can be synthesised by methods analogous to those described in e.g. Hamel, P.; Girard, M.; Tsou, N. N.; J. Heterocycl. 
HR P20080274 T3 analognim onima opisanim u, npr. Hamel,P., Girard,M.; Tsou.N.N., J. Heterocycl. Chem. 38.1999.
providing the said transmitter means (14) with a signal for compensating the residual difference in synchronization between the oscillation frequency of the local oscillator circuit (16) with respect to which these means are tuned and the universal reference signal frequency, in a second direct fast control loop configuration, when the slow control has not reached convergence. 
- < opskrbljivanje spomenutog odašiljača (14) signalom za nadoknađivanje preostale razlike u sinhronizaciji između oscilacijske frekvencije lokalnog oscilatorskog sklopa (16), s obzirom na to koji od tih sklopova je podešen na referentni signal univerzalne frekvencije, preko druge, brze, direktne upravljačke strukture petlje, kada spora upravljačka regulacija nije dosegla konvergenciju.
The make and break threaded pipe connection of Claims 1, 2 or 3, wherein the pin member has a pin nose region (21) and wherein the box ends of the coupling member each have a face region and wherein the pipe connection has a characteristic increased radial interlock at the box face regions due to an increased thread height in that region of the connection. 
„Make and break“ cijevni priključak s navojem iz zahtjeva 1, 2 ili 3, naznačen time da element klina ima prednji dio (21) klina i naznačen time da krajevi kutije elementa spojke svaki imaju prednji dio i naznačen time da cijevni priključak ima karakteristično povećano radijalno zaključavanje u prednjim dijelovima kutije zbog povećane visine navoja u tom području spoja.
The pneumatic speargun as claimed in claim 1, wherein the barrel (4) is open in the direction of the end discharge position of the piston (5). 
Pneumatska podvodna puška u skladu sa zahtjevom 1, pri čemu je cijev (4) otvorena u smjeru krajnjeg položaja pražnjenjnja klipa (5).
The present invention therefore specifically concerns a method for expanding adult stem cells from blood, particularly but not limited to peripheral blood, comprising the following steps. 
(54) Naziv izuma: METODA Å IRENJA ZA ODRASLE MATIČNE STANICE IZ KRVI, POSEBNO PERIFERNE KRVI, TE RELATIVNA UPORABA U MEDICINSKOM PODRUČJU
The integrated rotary mixer and disperser head (1) according to claim 9, wherein said serrations (26,27) have a generally castellation-like profile. 
Integrirana rotacijska miješalica 1 glava raspršivača (1) prema 9. tvrdnji gdje navedena nazupčenja (26, 27) imaju općenito nazubljeni profil.
selecting said patient for treatment with the specific binding member if the average HER2 gene copy number is greater than or equal to 10 per tumour cell. 
(ii) odabiranje spomenutog pacijenta za liječenje sa specifičnim veznim elementom ako je prosječan broj genskih kopija od HER2 veći od 10 ili je točno 10 po stanici tumora.
or a salt thereof, with a sulfonating agent to form a compound of formula (IV): 
(Ža) ili njegove soli, sa sredstvom za sulfoniranje, da se dobije spoj formule (IV):
wherein said at least one peptide is coupled or fused to a pharmaceutically acceptable carrier. 
60), pri čemu je taj najmanje jedan peptid spojen ili staljen na farmaceutski prihvatljivi nosač.
The stable oral pharmaceutical composition of claim 1, wherein at least 10% of the corticosteroid adheres to or is absorbed by the esophagus at least 15 seconds after oral administration of the stable oral pharmaceutical composition. 
Oralni farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1-5, gdje je upala jednjaka povezana s Barrettovim jednjakom, gastroezofagealnom refluksnom bolesti (GERD), neerozivnom refluksnom bolesti (NERD), ili erozivnim ezofagitisom.
A compound having the general formula I wherein 
Spoj koji ima opću formulu I Ri m
X is selected from the group consisting of O; 
X se izabire iz skupine koja obuhvaća NR, 0 iS;
culturing a cell harboring a nucleic acid encoding an ADAMTS protein in an animal protein-free culture medium; 
kultiviranje stanice koja sadrži nukleinsku kiselinu koja kodira ADAMTS protein u mediju za kultiviranje koji ne sadrži životinjske proteine;
The process of embodiment A, wherein the protein content based on dry matter is in a range of from 15% by weight to 85% by weight, and preferably in a range of from 50% by weight to 80% by weight. 
Postupak sukladno patentnom zahtjevu 1, naznačen time, da je sadržaj proteina baziran na suhoj tvari u rasponu od 50% do 80% težine.
wherein if the at least two amino acid positions selected for mutation are within the VH region, the substitution is at least two heavy chain amino acid positions selected from the group consisting of 12, 103 and 144 (according to AHo numbering convention; amino acid positions 11, 89 and 108 using Kabat numbering), and/or 
(B) mutacija najmanje tri aminokiselinske pozicije koje su odabrane za mutaciju, pri čemu se kod najmanje tri aminokiselinske pozicije radi o aminokiselinskim pozicijama 12, 103 i 144 jakog lanca (prema AHo-konvenciji numeriranja), te mutacija obuhvaća supstituciju aminokiseline na odabranim aminokiselinskim pozicijama protiv hidrofilne aminokiseline.
A process according to claim 5, wherein the polymethacrylate has an oxygen content of at least 25% by weight. 
Postupak prema zahtjevu 3, naznačen time što polimetakrilat ima sadržaj kisika od najmanje 25 masenih %.
The composition according to claim 1, wherein component (A) is 3difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl) amide and component (B2) is selected from the group consisting of difenoconazole, propiconazole, cyproconazole and epoxiconazole. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, le kao komponentu (B) ciprodinil.
While immunoglobulins fractions start to elute from the column at pH 6.1 and are completely eluted from the column at pH 4 using the MEP HYPERCEL® column (Ref. 
Iako do eluacije imunoglobulinskih frakcija sa kolone dolazi kod pH 6.1, a do kompletne eluacije sa kolone, kada se koristi kolona MEP HyperCel (Ref.
pharmaceutical composition comprising the compound of formula I or a salt, a N-oxide or a salt of a N-oxide of this compound as claimed in claim 7 together with customary pharmaceutical excipients and/or vehicles. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj formule I ili njegovu sol prema zahtjevu 4, zajedno s uobičajenim farmaceutskim pomoćnim sredstvima i/ili nosačima.
The conjugate according to claim 9, wherein the reactive groups at both ends are the same as or different from each other. 
Konjugat prema zahtjevu 12, naznačen time da su reaktivne skupine na oba kraja iste ili različite jedna od druge.
Salts and Derivatives 
Soli i derivati
A process according to claim 1, wherein the solid material is a particulate solid material having a mass median aerodynamic diameter of up to 10 um. 
Postupak u skladu s patentnim zahtjevom 1, pri čemu je čvrsti materijal čestični čvrsti materijal koji ima srednji maseni aerodinamički promjer do otprilike 10 um, poželjno do 5 um.
The fine particles <200 um could be used for a repeated extrusion process. 
Fine čestice koje su manje od 200 um se mogu ponovno upotrijebiti u postupku ekstruzije.
the treatment of latent tuberculosis; 
(a) liječenje latentne tuberkuloze;
The method of claim 25, wherein the a2 or a2B1 integrin is immobilized on a solid support. 
Metoda prema zahtjevu 25, gdje je a2 ili a2B1 integrin imobiliziran na krutoj podlozi.
The DNA detection kit of claim 17, wherein said at least one DNA molecule comprises SEQ ID NO:1, SEQ ID NO:2, or the complement thereof. 
DNA molekula ima SEQ ID NO. 1, SEQ ID NO: 2, ili njihove komplementarne sekvence, ili (1i) da navedeni kit sadrži par DNA molekula u skladu sa bilo kojem od zahtjeva 10 do 14.
obtaining a first image of each of said plurality of carrier substrates, after said dosage of active agent has been dispensed thereon; 
snima prvu sliku svakog od navedenih više nosivih supstrata (1000), nakon što se navedenu dozu aktivnog sredstva (2000) izda na njega;
wherein the composition comprises at least about 80 % (by wt) of polyethylene oxide and at least about 50 % (by wt) of polyethylene oxide having, based on rheological measurements, a molecular weight of at least 1,000,000. 
barem jedan aktivni agens, i pri čemu je formulacija matrica s produljenim otpuštanjem stvrdnuta pri temperaturi od barem oko 60 °C u vremenskom periodu od oko 1 minute i ima snagu pucanja od barem oko 110 N kada je podvrgnut indentacijskom testu.
Another advantage of the application of the above-mentioned alkali salts is that their price is low even in case of a pharmaceutical quality, so their application results in a reduction of the manufacturing costs. 
Sljedeća prednost primjene gore navedenih alkalnih soli je u tome što je njihova cijena niska čak i u slučaju da se radi o farmaceutskoj kakvoći, pa se njihovom primjenom smanjuje cijena proizvodnje.
The composition of any of Claims 1-4 further comprising at least one additional component selected from the group consisting of a surfactant, a solid diluent and a liquid diluent. 
Kompozicija prema bilo kojem od patentnih zahtjeva 1-4 koja dalje sadrži najmanje jednu dodatnu komponentu izabranu iz grupe koja se sastoji od surfaktanta, čvrstog razblaživača 1 tekućeg razblaživača.
cultivation of the host cell under conditions under which the cellobiohydrolase protein is expressed; and recovery of the cellobiohydrolase protein. In a preferred embodiment, the host cell is derived from the group consisting of Saccharomyces, Schizosaccharomyces, Kluyveromyces, Pichia, Hansenula, Aspergillus, Trichoderma, Penicillium, Candida and Yarrowina. 
Stanica domaćina naznačena time da je transformirana vektorom iz patentnog zahtjeva 5, gdje je po mogućnosti (i) stanica domaćina dobivena iz skupine koja se sastoji od pivskog kvasca, kvasca Schizosaccharomyces, kvasca Kluyveromyces, kvasca Pichia, kvasca Pichia, kvasca Hansenula, gljivica Aspergillus, gljivica Trichoderma, Kistaca, gljiva Chrysosporium, plijesni Chaetomium, plijesni Acremonium i kvasnice Candida i Yarrowina, i/ili
The process for preparing a vaccine composition as claimed in claim 17, wherein the conjugate obtained in a) is combined with diphtheria toxoid, tetanus toxoid, hepatitis B, 2, 3 or 5 acellular Bordetella pertussis antigens and also inactivated type 1, 2 and 3 polioviruses. 
Postupak za pripravu pripravka cjepiva prema zahtjevu 12 ili 13, naznačen time da se konjugat dobiven u koraku b) kombinira s toksoidom difterije, toksoidom tetanusa, antigenima hepatitisa B, 2, 3 ili 5 acelularnih antigena Bordetella pertussis 1 također inaktiviranim tipovima 1, 213 poliovirusa.
It is also useful to make sure that the cap and strap follow the contours of the inhaler in order to prevent dirt getting stuck in gaps and to enable the inhaler to stand upright on the base. 
Također je dobro ako se može postići da zatvarač i vrpca mogu biti prilagođeni obliku tijela inhalatora da se spriječi njegovo zaglavljivanje u nekoj šupljini i da bude moguće da inhalator stoji uspravno na osnovici.
at least a pressure sensor (22) for detecting an operating pressure internally of the plant and 
senzor (22) je konfiguriran za detektiranje tlaka ili protoka generiranog unutar postrojenja;
is a straight or branched C1-C9 alkyl, substituted with a group of the general formula (V): 
R9 je ravan ili razgranati C1-C9 alkil, supstituiran grupom opće formule (V):
The antisense oligomer according to [2] above, wherein the sugar moiety and/or the phosphate-binding region of at least one nucleotide constituting the oligonucleotide is modified. 
3. > Antisensni oligomer u skladu s patentnim zahtjevom 2, pri čemu je dio šećera i/ili područje vezivanja fosfata najmanje jednog nukleotida koji čini oligonukleotid, modificiran.
Preferably, the influenza virus strain that is associated with a pandemic outbreak and wherein the disease caused by these strains can be treated by the binding molecules of the present invention, is selected from the group consisting of H1N1, H5N1, H5N2, H5N8, H5N9, H2-based viruses, and H9N2. 
Antitijelo, ili njegov dio koji veže antigen, prema zahtjevu 6, naznačeni time da je navedeni soj virusa influence koji je povezan sa izbijanjem pandemije odabran iz skupine koja sadrži: HIN1, HSN1, H5N2, HSN8, HSN9, soj na osnovi H2, i H9N2.
3-Amino-5,6-bis-trifluoromethyl-pyridine-2-carboxylic acid ((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide, or a pharmaceutically acceptable salt thereof and a second active selected from osmotic agents, ENaC blockers, anti-inflammatory agents, bronchodilatory agents, antihistamine agents, anti-tussive agents, antibiotic agents and DNase drug substances, wherein the first and second actives may be in the same or different pharmaceutical composition. 
Farmaceutska kombinacija, naznačena time, da obuhvaća: prvi djelatni sastojak koji sadrži spoj ili njegovu farmaceutski prihvatljivu sol, prema bilo kojem od zahtjeva 1 do drugi djelatni sastojak odabran od sljedećih: osmotska sredstva, ENaC-blokatori, protuupalna sredstva, bronhodilatorna sredstva, antihistaminska sredstva, antitusivna sredstva, antibiotici i ljekovite DNase-supstance, pri čemu prvi i drugi djelatni sastojci mogu biti u istom ili u drugačijem farmaceutskom sastavu.
It comprises an amount of fucose on the total carbohydrate structures or on the carbohydrate structures at one particular glycosylation site of the protein molecule of the protein molecules in said protein molecule composition which is at least 5% less compared to the same amount of protein molecules in at least one protein molecule composition of the same protein molecule isolated from CHOdhfr− [ATCC No. 
(vi) sadrži količinu fukoze na ukupnim ugljikohidratnim strukturama ili na ugljikohidratnim strukturama na nekom određenom mjestu glikoziliranja u molekuli proteina kod navedenih molekula proteina u navedenom pripravku s molekulom proteina koja je najmanje 5% manja u usporedbi s istom količinom molekula proteina u pripravku s najmanje jednom molekulom proteina za istu molekulu proteina koja je izolirana iz ATCC No.
In optional step (e), a salt of the compound of the first aspect of this invention is formed. 
U opcionalnom koraku (e), nastaje sol spoja iz prvog aspekta .
The formulation according to claim 2, wherein adipic acid or adipate is present in an aqueous form of the pharmaceutical formulation in a concentration of between ≥ 5 and ≤ 25 mM. 
Formulacija prema zahtjevu 2, naznačena time, da se adipinska Kiselina ili adipat nalaze u vodenom obliku farmaceutske formulacije u koncentraciji od između > 51<25 mM.
a pharmaceutically acceptable aqueous carrier; wherein the brecanavir active ingredient is suspended. 
(b) farmaceutski prihvatljiv vodeni nosač; pri čemu je aktivni sastojak brekanavira suspendiran.
From the plate 51, some restraint teeth 58 project towards the insert 20, suitable for engaging and blocking the mobile interface 50 on the insert 20, connecting to windows 32 made in the external base 22 of the latter. 
Od ploče 51 su usmjereni zubi za povezivanje 58 prema umetku 20, koji su prikladni za zahvaćanje i za blokiranje pomičnog međusklopa 50 na umctak 20, koji zubi su spojeni na prozore 32 koji su načinjeni na vanjskoj bazi 22 umctka.
Food product characterized in that it comprises a mixture of slices of potatoes cooked in oil and popcorn, said slices of potatoes being potato chips and being present in a percentage by weight ranging approximately from 55% to 85% of the total weight of the food product and said pop-corn being present in a percentage by weight ranging approximately from 15% to 45% of the total weight of the food product. 
HR P20140511 T1 PATENTNI ZAHTJEVI Prehrambeni proizvod okarakteriziran time da sadrži mješavinu ploški krumpira kuhanih u ulju i kokica, gdje su ploške krumpira čips od krumpira i prisutne u masenom postotku od otprilike 55% do 85% od ukupne mase prehrambenog proizvoda i gdje su kokice prisutne u masenom postotku od otprilike 15% do 45% od ukupne mase prehrambenog proizvoda,
Best VCI scores of human VK compared with 158 VK Kabat Number6 
Najbolji VCI režultati za humani VK u usporedbi sa 158 VK iv
The compound of claim 19 wherein the syndrome, disorder or disease is related to appetite, metabolism, diabetes, glaucoma-associated intraocular pressure, social and mood disorders, seizures, substance abuse, learning, cognition or memory, organ contraction or muscle spasm, bowel disorders, respiratory disorders, locomotor activity or movement disorders, immune and inflammation disorders, unregulated cell growth. pain management or neuroprotection. 
Spoj prema zahtjevu 19 naznačen time da sindrom, poremećaj ili bolest je povezana sa apetitom, metabolizmom, dijabetesom, intraokularnim tlakom u vezi sa glaukomom, socijalnim poremećajima i poremećajima raspoloženja, napadima, zloupotrebom tvari, učenjem, opažanjem i/ili pamćenjem, kontrakcijom organa ili mišićnim spazmom, HR P20120159 T1 crijevnim poremećajima, respiratornim poremećajima, poremećajima lokomotorne aktivnosti ili poremećajima kretanja, imunološkim poremećajima ili upalnim poremećajima, nereguliranim rastom stanica ili neurozaštitom.
contacting the sample with AB-aggregates or with particles having AB-aggregate like surfaces and allowing the AB-specific antibodies to bind to the AB-aggregates, and 
stavljanje u doticaj uzorka s Aß-agregatima ili s kuglicama koje imaju Aß-agregate imobilizirane na svojoj površini, te dopuštanje Aß-specifičnim protutijelima da se vežu na Aß-agregate, i
Large artificial body of water affected by bacteria and microalgae and system for treating and maintaining it at low cost, comprising: 
PATENTNI ZAHTJEVI 1. - Veliko umjetno vodeno tijelo na koje utječu bakterije i mikroalge 1 sustav za njegovu obradu i održavanje uz niske troškove, te obuhvaća: